BIRMINGHAM, Ala., Oct. 22 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its thirdquarter 2009 financial results will be released on Thursday, October 29, 2009. áBioCryst will host a conference call and Web cast at 11:00 a.m. Eastern Time to discuss the financial results
The Web cast can be accessed by logging onto http://www.biocryst.com. áPlease connect to the Web site at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed. áTo participate in the conference call, please dial 1-888-297-0353 (United States) or 1-719-325-2266 (International). áNo passcode is needed for the call. áThe audio portion of the Web cast will be archived and available for replay for at least 14 days.
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst has progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Limited validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm .
SOURCE BioCryst Pharmaceuticals
Subscribe to our Free Newsletters!
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...View All